These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 32748788)

  • 1. Tailored design of protein nanoparticle scaffolds for multivalent presentation of viral glycoprotein antigens.
    Ueda G; Antanasijevic A; Fallas JA; Sheffler W; Copps J; Ellis D; Hutchinson GB; Moyer A; Yasmeen A; Tsybovsky Y; Park YJ; Bick MJ; Sankaran B; Gillespie RA; Brouwer PJ; Zwart PH; Veesler D; Kanekiyo M; Graham BS; Sanders RW; Moore JP; Klasse PJ; Ward AB; King NP; Baker D
    Elife; 2020 Aug; 9():. PubMed ID: 32748788
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structural basis for the development of avian virus capsids that display influenza virus proteins and induce protective immunity.
    Pascual E; Mata CP; Gómez-Blanco J; Moreno N; Bárcena J; Blanco E; Rodríguez-Frandsen A; Nieto A; Carrascosa JL; Castón JR
    J Virol; 2015 Mar; 89(5):2563-74. PubMed ID: 25520499
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design of Nanoparticulate Group 2 Influenza Virus Hemagglutinin Stem Antigens That Activate Unmutated Ancestor B Cell Receptors of Broadly Neutralizing Antibody Lineages.
    Corbett KS; Moin SM; Yassine HM; Cagigi A; Kanekiyo M; Boyoglu-Barnum S; Myers SI; Tsybovsky Y; Wheatley AK; Schramm CA; Gillespie RA; Shi W; Wang L; Zhang Y; Andrews SF; Joyce MG; Crank MC; Douek DC; McDermott AB; Mascola JR; Graham BS; Boyington JC
    mBio; 2019 Feb; 10(1):. PubMed ID: 30808695
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structural Characterization and Modeling of a Respiratory Syncytial Virus Fusion Glycoprotein Nanoparticle Vaccine in Solution.
    Krueger S; Curtis JE; Scott DR; Grishaev A; Glenn G; Smith G; Ellingsworth L; Borisov O; Maynard EL
    Mol Pharm; 2021 Jan; 18(1):359-376. PubMed ID: 33322901
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Elicitation of Protective Antibodies against 20 Years of Future H3N2 Cocirculating Influenza Virus Variants in Ferrets Preimmune to Historical H3N2 Influenza Viruses.
    Allen JD; Jang H; DiNapoli J; Kleanthous H; Ross TM
    J Virol; 2019 Feb; 93(3):. PubMed ID: 30429350
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of a Pan-H1 Influenza Vaccine.
    Darricarrère N; Pougatcheva S; Duan X; Rudicell RS; Chou TH; DiNapoli J; Ross TM; Alefantis T; Vogel TU; Kleanthous H; Wei CJ; Nabel GJ
    J Virol; 2018 Nov; 92(22):. PubMed ID: 30185594
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neutralizing Antibody Responses Induced by HIV-1 Envelope Glycoprotein SOSIP Trimers Derived from Elite Neutralizers.
    Schorcht A; van den Kerkhof TLGM; Cottrell CA; Allen JD; Torres JL; Behrens AJ; Schermer EE; Burger JA; de Taeye SW; Torrents de la Peña A; Bontjer I; Gumbs S; Ozorowski G; LaBranche CC; de Val N; Yasmeen A; Klasse PJ; Montefiori DC; Moore JP; Schuitemaker H; Crispin M; van Gils MJ; Ward AB; Sanders RW
    J Virol; 2020 Nov; 94(24):. PubMed ID: 32999024
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design and Characterization of a Computationally Optimized Broadly Reactive Hemagglutinin Vaccine for H1N1 Influenza Viruses.
    Carter DM; Darby CA; Lefoley BC; Crevar CJ; Alefantis T; Oomen R; Anderson SF; Strugnell T; Cortés-Garcia G; Vogel TU; Parrington M; Kleanthous H; Ross TM
    J Virol; 2016 May; 90(9):4720-4734. PubMed ID: 26912624
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Elicitation of Protective Antibodies against a Broad Panel of H1N1 Viruses in Ferrets Preimmune to Historical H1N1 Influenza Viruses.
    Carter DM; Darby CA; Johnson SK; Carlock MA; Kirchenbaum GA; Allen JD; Vogel TU; Delagrave S; DiNapoli J; Kleanthous H; Ross TM
    J Virol; 2017 Dec; 91(24):. PubMed ID: 28978709
    [TBL] [Abstract][Full Text] [Related]  

  • 10. N-Linked Glycans and K147 Residue on Hemagglutinin Synergize To Elicit Broadly Reactive H1N1 Influenza Virus Antibodies.
    Huang Y; Owino SO; Crevar CJ; Carter DM; Ross TM
    J Virol; 2020 Feb; 94(6):. PubMed ID: 31852790
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structural and functional evaluation of de novo-designed, two-component nanoparticle carriers for HIV Env trimer immunogens.
    Antanasijevic A; Ueda G; Brouwer PJM; Copps J; Huang D; Allen JD; Cottrell CA; Yasmeen A; Sewall LM; Bontjer I; Ketas TJ; Turner HL; Berndsen ZT; Montefiori DC; Klasse PJ; Crispin M; Nemazee D; Moore JP; Sanders RW; King NP; Baker D; Ward AB
    PLoS Pathog; 2020 Aug; 16(8):e1008665. PubMed ID: 32780770
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intranasal Nanoparticle Vaccination Elicits a Persistent, Polyfunctional CD4 T Cell Response in the Murine Lung Specific for a Highly Conserved Influenza Virus Antigen That Is Sufficient To Mediate Protection from Influenza Virus Challenge.
    Nelson SA; Dileepan T; Rasley A; Jenkins MK; Fischer NO; Sant AJ
    J Virol; 2021 Jul; 95(16):e0084121. PubMed ID: 34076479
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevention of influenza virus infection and transmission by intranasal administration of a porous maltodextrin nanoparticle-formulated vaccine.
    Quan Le M; Ye L; Bernasconi V; Carpentier R; Fasquelle F; Lycke N; Staeheli P; Betbeder D
    Int J Pharm; 2020 May; 582():119348. PubMed ID: 32325240
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Morphological characterization of a plant-made virus-like particle vaccine bearing influenza virus hemagglutinins by electron microscopy.
    Lindsay BJ; Bonar MM; Costas-Cancelas IN; Hunt K; Makarkov AI; Chierzi S; Krawczyk CM; Landry N; Ward BJ; Rouiller I
    Vaccine; 2018 Apr; 36(16):2147-2154. PubMed ID: 29550194
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative Immunogenicity of Bacterially Expressed Soluble Trimers and Nanoparticle Displayed Influenza Hemagglutinin Stem Immunogens.
    Kar U; Khaleeq S; Garg P; Bhat M; Reddy P; Vignesh VS; Upadhyaya A; Das M; Chakshusmathi G; Pandey S; Dutta S; Varadarajan R
    Front Immunol; 2022; 13():890622. PubMed ID: 35720346
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intranasal vaccination with influenza HA/GO-PEI nanoparticles provides immune protection against homo- and heterologous strains.
    Dong C; Wang Y; Gonzalez GX; Ma Y; Song Y; Wang S; Kang SM; Compans RW; Wang BZ
    Proc Natl Acad Sci U S A; 2021 May; 118(19):. PubMed ID: 33941704
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Generation of DelNS1 Influenza Viruses: a Strategy for Optimizing Live Attenuated Influenza Vaccines.
    Wang P; Zheng M; Lau SY; Chen P; Mok BW; Liu S; Liu H; Huang X; Cremin CJ; Song W; Chen Y; Wong YC; Huang H; To KK; Chen Z; Xia N; Yuen KY; Chen H
    mBio; 2019 Sep; 10(5):. PubMed ID: 31530680
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Implementing sequence-based antigenic distance calculation into immunological shape space model.
    Anderson CS; Sangster MY; Yang H; Mariani TJ; Chaudhury S; Topham DJ
    BMC Bioinformatics; 2020 Jun; 21(1):256. PubMed ID: 32560624
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Covalent coupling of HIV-1 glycoprotein trimers to biodegradable calcium phosphate nanoparticles via genetically encoded aldehyde-tags.
    Damm D; Kostka K; Weingärtner C; Wagner JT; Rojas-Sánchez L; Gensberger-Reigl S; Sokolova V; Überla K; Epple M; Temchura V
    Acta Biomater; 2022 Mar; 140():586-600. PubMed ID: 34968725
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Complement C3 Plays a Key Role in Inducing Humoral and Cellular Immune Responses to Influenza Virus Strain-Specific Hemagglutinin-Based or Cross-Protective M2 Extracellular Domain-Based Vaccination.
    Kim YJ; Kim KH; Ko EJ; Kim MC; Lee YN; Jung YJ; Lee YT; Kwon YM; Song JM; Kang SM
    J Virol; 2018 Oct; 92(20):. PubMed ID: 30068650
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.